J&J plans to cut workforce by up to 4%

Johnson & Johnson said today it would reduce its 120,500-member global work force by 3% to 4%, or as many as 4,800 jobs, through attrition and hiring freezes.
The cuts would focus mainly on the pharmaceutical unit, which faces a number of patent expirations over the next few years and the company's Cordis stent making unit.
J&J did not disclose exactly where the job cuts will take place.
J&J is targeting 2008 pretax savings of $1.3 billion - $1.6 billion as a result of the job reductions.
Today's announcement comes just two weeks after the company lowered its sales-growth forecast due to safety concerns surrounding its blockbuster anti-anemia drug Procrit and drug-coated heart stents.
"Throughout our history, we have always taken a thoughtful, disciplined approach to address the challenges we face," said J&J CEO William Weldon in a statement. "These actions we are taking to improve our cost structure will enable us to continue investing for future growth and profitability."
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.